Hexal (Germany)

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 10 of 43 papers

  • Open Access
  • Addendum

Corrigendum to "The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab" [Clin Ther. 2024;46:916-926

  • Oct 01, 2025
  • Clinical therapeutics
  • Barbara Vogg +8
  • Open Access
  • Research Article

Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA).

  • Apr 25, 2025
  • Drugs in R&D
  • Diamant Thaçi +8
  • Open Access
  • Research Article

Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary.

  • Apr 13, 2025
  • Immunotherapy
  • Marc Schmalzing +14
  • Open Access
  • Research Article

Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)

  • Feb 20, 2025
  • Urologia Internationalis
  • Bernd J Schmitz-Dräger +10
  • Research Article
  • Citations15

Signal-to-noise ratio to assess magnitude, kinetics and impact on pharmacokinetics of the immune response to an adalimumab biosimilar.

  • Nov 30, 2023
  • Bioanalysis
  • Davide Guerrieri +6
  • Research Article

Neudefinition und Messung der Grenzschichtdicke an einer angeströmten Fläche – Ermittlung thermodynamischer und aerodynamischer Größen hieraus

  • Apr 01, 2023
  • Bauphysik
  • Erhard Mayer +1
  • Abstract

Effet en vie réelle, sécurité et données rapportées par les patients atteints de rhumatismes inflammatoires chroniques traités par le biosimilaire de l’étanercept GP2015 : résultats de l’étude COMPACT

  • Dec 01, 2022
  • Revue du Rhumatisme
  • Y Allanore +6
  • Open Access
  • Abstract

S1057 A Randomized Phase I Study Comparing Pharmacokinetics, Safety and Immunogenicity of High Concentration Formulation (100 mg/mL) With GP2017 Formulation (50 mg/mL), an Adalimumab Biosimilar, in Healthy Male Subjects

  • Oct 01, 2022
  • American Journal of Gastroenterology
  • Juan Carlos Rondon +5
  • Open Access
  • Abstract

553P Innovative medicinal products and early access provision: Challenges and opportunities to improve access to care for oncology patients

  • Sep 01, 2021
  • Annals of Oncology
  • A Krendyukov +3
  • Abstract
  • Citations2

A Systematic Literature Review of Overall Survival and Delivered Dose Intensity in Cancer Patients Receiving Chemotherapy and G-CSF in Randomized Control Trials

  • Jun 25, 2021
  • Blood
  • Gary H Lyman +3
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.